-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Bispecific Antibodies: A Playbook for Relapsed/Refractory Follicular Lymphoma

Sponsor: Genmab and AbbVie
Program: Friday Satellite Symposia
Hematology Disease Topics & Pathways:
Lymphomas, Education, Diseases, Treatment Considerations, Lymphoid Malignancies, Adverse Events
Friday, December 6, 2024: 3:00 PM-6:00 PM
Marriott Grand Ballroom 11-13 (Marriott Marquis San Diego Marina)
Chair:
Joshua Brody, MD, Icahn School of Medicine at Mount Sinai
Disclosures:
No relevant conflicts of interest to declare.
Speakers:
Krish Patel, MD, Swedish Cancer Institute and Lorna Warwick, Lymphoma Coalition
Disclosures:
Patel: Curis, Inc: Research Funding; Trillium Therapeutics/Pfizer: Consultancy, Research Funding; Fate Therapeutics: Research Funding; Genentech/Roche: Consultancy, Research Funding; Kite: Consultancy, Research Funding, Speakers Bureau; Loxo Oncology: Consultancy, Research Funding; MEI Pharma: Consultancy, Research Funding; Merck: Consultancy, Research Funding; Morphosys: Consultancy; Nurix: Research Funding; Pharmacyclics/Janssen: Consultancy, Research Funding; Sunesis Pharmaceuticals: Consultancy, Research Funding; TG Therapeutics: Consultancy, Speakers Bureau; Epizyme: Consultancy, Research Funding; Caribou Biosciences: Consultancy; CRISPR Therapeutics: Research Funding; Bristol Myers Squibb: Consultancy, Research Funding, Speakers Bureau; BeiGene: Consultancy; AstraZeneca: Consultancy, Research Funding, Speakers Bureau; ADC Therapeutics: Consultancy; Adaptive Biotechnologies: Research Funding; AbbVie: Consultancy; Xencor: Consultancy, Research Funding.
This will be a 90-minute symposium featuring 2 expert hematologists/oncologists and a patient/patient advocate, as they discuss the role of bispecific antibodies in the treatment of 3L+ R/R FL. Together panelists will review best practices for assessing and applying the latest data on bispecific antibodies, as well as strategies to enhance SDM and patient-centered care.